{
    "Clinical Trial ID": "NCT00436566",
    "Intervention": [
        "INTERVENTION 1: ",
        "  AC/PTL",
        "  Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed diagnosis of early-stage breast cancer",
        "  HER2 positive by immunohistochemistry (IHC) (3+) or fluorescent in situ hybridization (FISH)",
        "  Ductal carcinoma in situ (DCIS) components should not be counted in the determination of degree of IHC staining or FISH amplification",
        "  No locally advanced tumors (i.e., T4) at diagnosis, including the following:",
        "  Tumors fixed to chest wall",
        "  Peau d'orange",
        "  Skin ulcerations or nodules",
        "  Clinical inflammatory changes (e.g., diffuse brawny cutaneous induration with an erysipeloid edge)",
        "  Has undergone mastectomy or lumpectomy with axillary node or sentinel node dissection within the past 84 days",
        "  Patients who have undergone a mastectomy must meet the following criteria:",
        "  No evidence of gross or microscopic tumor (i.e., invasive DCIS) at the surgical resection margins noted in final surgery or pathology reports",
        "  Patients with close margins are eligible",
        "  Radiation therapy is required for 4 or more positive lymph nodes and must be started after completion of chemotherapy",
        "  Patients who have undergone a lumpectomy with axillary node or sentinel node dissection must meet the following criteria:",
        "  No evidence of invasive cancer or DCIS at the surgical resection margins",
        "  No gross residual adenopathy",
        "  Planning to undergo radiation therapy to the breast with or without regional lymphatics after completion of chemotherapy",
        "  No active hepatic or biliary disease",
        "  Patients with liver metastases, stable chronic liver disease, Gilbert's syndrome, or asymptomatic gallstones are eligible",
        "  Hormone receptor status:",
        "  Estrogen receptor and progesterone receptor status known",
        "  PATIENT CHARACTERISTICS:",
        "  Male or female",
        "  Menopausal status not specified",
        "  ECOG performance status 0-2",
        "  Absolute neutrophil count  1,500/mm\u00b3",
        "  Platelet count  100,000/mm\u00b3",
        "  Hemoglobin  10.0 g/dL",
        "  Bilirubin  1.5 times upper limit of normal (ULN)",
        "  AST and ALT  2.5 times ULN",
        "  Alkaline phosphatase  2.5 times ULN",
        "  Creatinine normal OR creatinine clearance  60 mL/min",
        "  LVEF  50% by MUGA scan or echocardiogram",
        "  Able to complete questionnaire(s) by themselves or with assistance",
        "  Able and willing to provide blood and tissue samples",
        "  No known sensitivity to benzyl alcohol",
        "  No sensory neuropathy  grade 2",
        "  No active cardiac disease, including any of the following:",
        "  Myocardial infarction within the past 6 months",
        "  Prior or concurrent congestive heart failure",
        "  Prior or concurrent arrhythmia or cardiac valvular disease requiring medications or that is clinically significant",
        "  Uncontrolled hypertension, defined as diastolic blood pressure (BP) >100 mm Hg or systolic BP > 200 mm Hg on 2 separate occasions  14 days apart",
        "  Clinically significant pericardial effusion",
        "  Prior or concurrent uncontrolled or symptomatic angina",
        "  Other cardiac condition that, in the opinion of the treating physician, would put the patient at hazardous risk",
        "  No history of allergic reactions attributed to compounds of similar chemical or biologic composition as lapatinib ditosylate",
        "  No uncontrolled intercurrent illness including, but not limited to, the following:",
        "  Ongoing or active infection",
        "  Psychiatric illness or social situations that would preclude study compliance",
        "  Able to swallow and retain oral medication",
        "  No history of gastrointestinal (GI) disease resulting in an inability to take oral medication, including any of the following:",
        "  Malabsorption syndrome",
        "  Requirement for IV alimentation",
        "  Prior surgical procedures affecting absorption",
        "  Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception during and for 6 months after completion of study treatment",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  No prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer",
        "  No primary breast radiation therapy as part of breast-conserving treatment",
        "  No prior anthracycline or taxane therapy for any malignancy",
        "  No prior epidermal growth factor receptor-targeting therapies (e.g., gefitinib, cetuximab, erlotinib hydrochloride, rituximab, trastuzumab [Herceptin\u00ae], lapatinib ditosylate, panitumumab, or nimotuzumab)",
        "  At least 14 days since prior and no concurrent CYP3A4 inducers, including the following:",
        "  Rifamycin-class antibiotics (e.g., rifampin, rifabutin, or rifapentine)",
        "  Anticonvulsants (e.g., phenytoin, carbamazepine, or barbiturates [e.g., phenobarbital])",
        "  Antiretrovirals (e.g., efavirenz or nevirapine)",
        "  Glucocorticoids (e.g., oral cortisone, hydrocortisone, prednisone, methylprednisolone, or dexamethasone)",
        "  Daily oral dexamethasone  1.5 mg (or equivalent) allowed",
        "  Modafinil",
        "  Hypericum perforatum (St. John's wort)",
        "  At least 7 days since prior and no concurrent CYP3A4 inhibitors, including the following:",
        "  Antibiotics (e.g., clarithromycin, erythromycin, or troleandomycin)",
        "  Antifungals (e.g., itraconazole, ketoconazole, fluconazole [> 150 mg daily], or voriconazole)",
        "  Antiretrovirals and protease inhibitors (e.g., delaviridine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, or lopinavir)",
        "  Calcium channel blockers (e.g., verapamil or diltiazem)",
        "  Antidepressants (e.g., nefazodone or fluvoxamine)",
        "  Gastrointestinal agents (e.g., cimetidine or aprepitant)",
        "  Grapefruit and grapefruit juice",
        "  At least 6 months since prior and no concurrent amiodarone",
        "  No herbal or alternative medicines or supplements  14 days before, during, and for 30 days after completion of study treatment",
        "  No concurrent hormonal agents (e.g., birth control pills, ovarian hormonal replacement therapy, or raloxifene)",
        "  Adjuvant hormonal agents (e.g., tamoxifen, aromatase inhibitors) allowed after completion of chemotherapy as part of treatment for breast cancer",
        "  No concurrent antiretroviral therapy for HIV-positive patients",
        "  No concurrent digitalis or beta-blockers for congestive heart failure",
        "  No concurrent arrhythmia or angina pectoris medication",
        "  No other concurrent investigational agents or anticancer therapies, including cytotoxic agents or immunotherapy"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment",
        "  [Not Specified]",
        "  Time frame: 6 months",
        "Results 1: ",
        "  Arm/Group Title: AC/PTL",
        "  Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.",
        "  Overall Number of Participants Analyzed: 109",
        "  Measure Type: Number",
        "  Unit of Measure: participants  0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 17/108 (15.74%)",
        "  Febrile neutropenia 1/108 (0.93%)",
        "  Left ventricular failure 1/108 (0.93%)",
        "  Diarrhea 6/108 (5.56%)",
        "  Fatigue 1/108 (0.93%)",
        "  Pneumonia 1/108 (0.93%)",
        "  Skin infection 1/108 (0.93%)",
        "  Urinary tract infection 1/108 (0.93%)",
        "  Alanine aminotransferase increased 1/108 (0.93%)",
        "  Aspartate aminotransferase increased 1/108 (0.93%)",
        "  Leukopenia 2/108 (1.85%)"
    ]
}